New Alzheimer's drug progress in trials

News
1

https://www.genengnews.com/gen-articles/the-scoop-alzheimers-drug-tries-to-build-up-a-head-of-steam/6285

"Dr. Ryan added that Neurotrope expects to begin the confirmatory study in the first half of 2018.

In the clinical work ahead, bryostatin may experience additional ups and downs. Regardless, the drug—a protein kinase C epsilon (PKCε) activator derived from a marine animal—can lay claim to an intriguing mechanism of action. “This molecule penetrates the blood-brain barrier to activate synaptic growth factors and thereby induce the production of new, mature synapses, activate signaling pathways that protect against neuronal death, reduce the levels of amyloid-beta oligomers, and thus reduce the production of extraneuronal amyloid plaques, prevent hyperphosphorylation of tau, and thus the generation of intraneuronal fibrillary tangles—and, through all of these mechanisms, potentially restore cognitive functions,” explained Dr. Ryan."

6 Likes
2

Thank you for posting @twinklestars 101010

1 Like
3

Found this in relation to bryostatin (and other drugs) and schizophrenia:

“Bryostatin is a partial agonist at multiple protein kinase isoforms (including protein kinase D, the product of PRKD1), which is being tested for its antineoplastic properties.27 Notably, protein kinase D modulates the E-cadherin/β-catenin pathway, which is critical for synaptic plasticity.28 Although a repurposing of bryostatin may be premature, especially given limited understanding of its pharmacokinetics, this represents a promising avenue for further study.”

https://www.nature.com/articles/mp201528

2 Likes